Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) for drug discovery and mechanism of action (MOA) research

Pre-Made Inbakicept biosimilar, Fusion Protein: Recombinant therapeutic protein targeting IL15 fused with human IGHG1 Fc (Fragment constant) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Inbakicept is a human IL-15 superagonist with immunostimulatory properties with promising anti-cancer treatment and it is also being investigated as an HIV treatment. Inbakicept is a soluble complex consisting of two protein subunits of a human interleukin (IL)-15 variant (nogapendekin alfa) bound with high affinity to a dimeric human IL-15 receptor ¦Á (IL-15 R¦Á) sushi domain/human IgG1 Fc fusion protein. This fusion protein has been designed to simulate the normal mechanism of action of IL-15 where IL-15 and IL-15 R¦Á are coordinately expressed by antigen-presenting cells (monocytes and dendritic cells) and presented in trans to neighboring NK cells or CD8 + T cells expressing the CD122/CD132 receptor complex.